|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.05.26 - 12:06
|
Novo CEO Says No Intention to Lower Wegovy Prices Further (Bloomberg)
|
|
|
Novo Nordisk CEO Mike Doustdar discusses the drugmaker's Wegovy obesity pill which fueled sales in the first quarter. Novo is "very optimistic" on the medication despite competition from Eli Lilly, Doustdar tells Bloomberg Television, and the firm doesn't anticipate any price reductions. (Source: Bloomberg)...
|
|
|
|
|
05.05.26 - 21:16
|
Eli Lilly Aktie: FDA-Meldung sorgt für Druck - Kaufchance? (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Eli Lilly-Aktienanalyse von Wolfe Research:
Die Analysten von Wolfe Research stufen die Aktie von Eli Lilly and Company (ISIN: US5324571083, WKN: 858560, Ticker-Symbol: LLY, NYSE-Symbol: LLY) mit dem Rating "outperform" ein.
Wolfe Research weise darauf hin, dass die FDA am 30. [mehr]...
|
|
|
05.05.26 - 20:46
|
Eli Lilly Aktie: Rekordzahlen - GLP-1-Boom treibt Gewinne nach oben (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Eli Lilly-Aktienanalyse von der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), stuft in einer aktuellen Aktienanalyse die Aktie von Eli Lilly and Company (ISIN: US5324571083, WKN: 858560, Ticker-Symbol: LLY, NYSE-Symbol: LLY) in seiner Ersteinschätzung mit "kaufen" ein. [mehr]...
|
|
|
05.05.26 - 16:54
|
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show (24/7 Wall St.)
|
|
|
Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company's Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show...
|
|
|
|
|
|
|
05.05.26 - 15:03
|
Zifo′s SiEE Boston Summit Charts New Roadmap for ′Practical AI′ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality (PR Newswire)
|
|
|
BOSTON, May 5, 2026 /PRNewswire/ -- Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk,......
|
|
|
|
|
|
|
|
|
|
|
04.05.26 - 22:54
|
Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125% (24/7 Wall St.)
|
|
|
The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be replaced with the “Mounjaro economy” now that Eli Lilly is controlling 60% of the GLP-1 market. Lilly's Q1 2026 earnings report backs that up. Lilly's Dominance, by the Numbers Eli Lilly (NYSE:LLY) ... Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%...
|
|
|
04.05.26 - 21:00
|
Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months (24/7 Wall St.)
|
|
|
Eli Lilly (NYSE:LLY) just delivered one of the strongest first quarters in big pharma history, but shares have pulled back sharply from their February peak. That gap between operating performance and stock price is where our model sees opportunity. Our 24/7 Wall St. price target for Eli Lilly is $1,133.12 over the next 12 months, ... Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
